Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria

S. Krishna, T. Agbenyega, B. J. Angus, G. Bedu-Addo, G. Ofori-Amanfo, G. Henderson, I. S F Szwandt, P. W. Stacpoole

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Actic acidosis frequently complicates severe malaria in African children, and is a strong independent predictor of mortality. We tested the hypothesis that sodium dichloroacetate (DCA), an activator of pyruvate dehydrogenase, rapidly reduces hyperlactataemia in this patient population. Eighteen children with severe malaria and capillary plasma lactate 5 mM were randomized to receive either intramuscular quinine plus a single 50 mg/kg intravenous infusion of DCA in saline, or quinine plus intravenous saline alone. Two patients in each treatment group died following randomization. Thirty minutes after treatment, the mean plasma lactate was 28% below pretreatment baseline values in the DCA group, but was unchanged in the placebo group. Throughout the first 4 h after treatment, mean plasma lactate in the DCA-treated patients was significantly less than that in controls (p = 0.003). Thereafter, mean plasma lactate declined in both groups and was <2 mM 10 h after treatment. DCA was well tolerated and did not alter quinine pharmacokinetics. A single intravenous dose of DCA rapidly improved lactic acidosis in African children with severe malaria, suggesting that DCA may be a useful adjunct in the initial treatment of these patients, and may increase their chance of survival by improving a major complication of their illness.

Original languageEnglish (US)
Pages (from-to)341-349
Number of pages9
JournalQJM
Volume88
Issue number5
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Lactic Acidosis
Malaria
Pharmacokinetics
Quinine
Lactic Acid
Dichloroacetic Acid
Therapeutics
Random Allocation
Acidosis
Intravenous Infusions
Placebos
Survival
Mortality
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Krishna, S., Agbenyega, T., Angus, B. J., Bedu-Addo, G., Ofori-Amanfo, G., Henderson, G., ... Stacpoole, P. W. (1995). Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. QJM, 88(5), 341-349. https://doi.org/10.1093/oxfordjournals.qjmed.a069075

Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. / Krishna, S.; Agbenyega, T.; Angus, B. J.; Bedu-Addo, G.; Ofori-Amanfo, G.; Henderson, G.; Szwandt, I. S F; Stacpoole, P. W.

In: QJM, Vol. 88, No. 5, 1995, p. 341-349.

Research output: Contribution to journalArticle

Krishna, S, Agbenyega, T, Angus, BJ, Bedu-Addo, G, Ofori-Amanfo, G, Henderson, G, Szwandt, ISF & Stacpoole, PW 1995, 'Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria', QJM, vol. 88, no. 5, pp. 341-349. https://doi.org/10.1093/oxfordjournals.qjmed.a069075
Krishna, S. ; Agbenyega, T. ; Angus, B. J. ; Bedu-Addo, G. ; Ofori-Amanfo, G. ; Henderson, G. ; Szwandt, I. S F ; Stacpoole, P. W. / Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. In: QJM. 1995 ; Vol. 88, No. 5. pp. 341-349.
@article{ff9c8c289a9c49aebd22f9a8993f4222,
title = "Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria",
abstract = "Actic acidosis frequently complicates severe malaria in African children, and is a strong independent predictor of mortality. We tested the hypothesis that sodium dichloroacetate (DCA), an activator of pyruvate dehydrogenase, rapidly reduces hyperlactataemia in this patient population. Eighteen children with severe malaria and capillary plasma lactate 5 mM were randomized to receive either intramuscular quinine plus a single 50 mg/kg intravenous infusion of DCA in saline, or quinine plus intravenous saline alone. Two patients in each treatment group died following randomization. Thirty minutes after treatment, the mean plasma lactate was 28{\%} below pretreatment baseline values in the DCA group, but was unchanged in the placebo group. Throughout the first 4 h after treatment, mean plasma lactate in the DCA-treated patients was significantly less than that in controls (p = 0.003). Thereafter, mean plasma lactate declined in both groups and was <2 mM 10 h after treatment. DCA was well tolerated and did not alter quinine pharmacokinetics. A single intravenous dose of DCA rapidly improved lactic acidosis in African children with severe malaria, suggesting that DCA may be a useful adjunct in the initial treatment of these patients, and may increase their chance of survival by improving a major complication of their illness.",
author = "S. Krishna and T. Agbenyega and Angus, {B. J.} and G. Bedu-Addo and G. Ofori-Amanfo and G. Henderson and Szwandt, {I. S F} and Stacpoole, {P. W.}",
year = "1995",
doi = "10.1093/oxfordjournals.qjmed.a069075",
language = "English (US)",
volume = "88",
pages = "341--349",
journal = "QJM - Monthly Journal of the Association of Physicians",
issn = "1460-2725",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria

AU - Krishna, S.

AU - Agbenyega, T.

AU - Angus, B. J.

AU - Bedu-Addo, G.

AU - Ofori-Amanfo, G.

AU - Henderson, G.

AU - Szwandt, I. S F

AU - Stacpoole, P. W.

PY - 1995

Y1 - 1995

N2 - Actic acidosis frequently complicates severe malaria in African children, and is a strong independent predictor of mortality. We tested the hypothesis that sodium dichloroacetate (DCA), an activator of pyruvate dehydrogenase, rapidly reduces hyperlactataemia in this patient population. Eighteen children with severe malaria and capillary plasma lactate 5 mM were randomized to receive either intramuscular quinine plus a single 50 mg/kg intravenous infusion of DCA in saline, or quinine plus intravenous saline alone. Two patients in each treatment group died following randomization. Thirty minutes after treatment, the mean plasma lactate was 28% below pretreatment baseline values in the DCA group, but was unchanged in the placebo group. Throughout the first 4 h after treatment, mean plasma lactate in the DCA-treated patients was significantly less than that in controls (p = 0.003). Thereafter, mean plasma lactate declined in both groups and was <2 mM 10 h after treatment. DCA was well tolerated and did not alter quinine pharmacokinetics. A single intravenous dose of DCA rapidly improved lactic acidosis in African children with severe malaria, suggesting that DCA may be a useful adjunct in the initial treatment of these patients, and may increase their chance of survival by improving a major complication of their illness.

AB - Actic acidosis frequently complicates severe malaria in African children, and is a strong independent predictor of mortality. We tested the hypothesis that sodium dichloroacetate (DCA), an activator of pyruvate dehydrogenase, rapidly reduces hyperlactataemia in this patient population. Eighteen children with severe malaria and capillary plasma lactate 5 mM were randomized to receive either intramuscular quinine plus a single 50 mg/kg intravenous infusion of DCA in saline, or quinine plus intravenous saline alone. Two patients in each treatment group died following randomization. Thirty minutes after treatment, the mean plasma lactate was 28% below pretreatment baseline values in the DCA group, but was unchanged in the placebo group. Throughout the first 4 h after treatment, mean plasma lactate in the DCA-treated patients was significantly less than that in controls (p = 0.003). Thereafter, mean plasma lactate declined in both groups and was <2 mM 10 h after treatment. DCA was well tolerated and did not alter quinine pharmacokinetics. A single intravenous dose of DCA rapidly improved lactic acidosis in African children with severe malaria, suggesting that DCA may be a useful adjunct in the initial treatment of these patients, and may increase their chance of survival by improving a major complication of their illness.

UR - http://www.scopus.com/inward/record.url?scp=0029058933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029058933&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.qjmed.a069075

DO - 10.1093/oxfordjournals.qjmed.a069075

M3 - Article

VL - 88

SP - 341

EP - 349

JO - QJM - Monthly Journal of the Association of Physicians

JF - QJM - Monthly Journal of the Association of Physicians

SN - 1460-2725

IS - 5

ER -